Alzheimer’s Drug Slows Disease Progression in Trial
Eisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval.
Dow Jones & Company, Inc. 4300 U.S. Route 1 North Monmouth Junction, NJ 08852 You are currently subscribed as newsletter@newslettercollector.com. For further assistance, please contact Customer Service at support@wsj.com or 1-800-JOURNAL.
Copyright 2022 Dow Jones & Company, Inc. | All Rights Reserved.